Vaccine makers scramble to assess the Omicron Covid strain – Boston, Massachusetts

Boston, Massachusetts 2021-11-29 09:25:37 –

NSGood morning everyone. Welcome to the next week. Despite the hard news of the coronavirus, I think the long weekend break somehow relaxed and rejuvenated on our side of the pond anyway. But this was predictable, wasn’t it? In any case, a new cycle of online calling and deadlines awaits, so we’re dealing with it by engaging in regular rituals — brewing a cup of stimulus. Our choice today is seasonal peppermint mocha. Please feel free to join us. Meanwhile, here is the latest lineup of items for you to peruse and digest. Have a great day and conquer the world. And of course, stay in touch. We value your private notes and juicy tips. …

Vaccine makers spend weeks assessing the dangers and potential impacts of the new Omicron variant of Covid-19, but they are already competing to develop ways to combat it., The Wall Street Journal I will explain. So far, researchers at vaccine companies say it’s too early to decide on a course of action. Over the next few weeks, they will monitor whether infections from new variants lead to a surge in hospitalizations and deaths. This indicates that Omicron is more dangerous than previous coronavirus variants. Vaccine companies are also waiting for data from ongoing lab tests to see if existing vaccines produce sufficient neutralizing antibodies to fight new mutants.

Sign up for STAT + to unlock this article and enjoy the first 30 days for free!

let’s start

Vaccine makers scramble to assess the Omicron Covid strain Source link Vaccine makers scramble to assess the Omicron Covid strain

Back to top button